This BlackRock stock just rocketed 70%

Core Viewpoint - Exicure has experienced a significant stock price rally due to promising Phase 2 trial results for its investigational drug burixafor, which is designed for hematopoietic progenitor cell mobilization in multiple myeloma patients [1][3]. Group 1: Stock Performance - Exicure shares surged 70% in pre-market trading to approximately $9, following a previous close of $5.33, marking a year-to-date decline of 64.89% [1]. - The early-morning rally was a response to the positive trial results, indicating a strong market reaction to the new data [3]. Group 2: Clinical Trial Results - Nearly 90% of trial participants achieved the required CD34+ cell thresholds within two leukapheresis sessions when treated with burixafor in combination with propranolol and G-CSF [4]. - The therapy demonstrated effectiveness in patients previously treated with daratumumab, a group that typically has lower mobilization success [5]. - Burixafor's rapid activity was highlighted, with peak CD34+ cell levels appearing within an hour, distinguishing it from other drugs in the same class [5]. Group 3: Institutional Ownership - Despite its small size and previous decline, Exicure has maintained a presence in the portfolios of major institutional investors, including BlackRock, Carlyle Group, Vanguard, Geode Capital Management, and UBS Group [6][7]. - As of September 30, 2025, BlackRock held 5,730 shares of Exicure, indicating continued interest from professional investors [6].